Skip to main content

Table 4 Comparison masitinib safety profile in nononcology phase 2 studies

From: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

 

Phase 2 nononcology studiesa

Alzheimer study

 

Controlled Masitinib

( n = 79)

Placebo

( n = 25)

Noncontrolled Masitinib

( n = 137)

Masitinib ( n = 26)

Placebo

( n = 8)

At least one AE

73 (92%)

19 (76%)

122 (89%)

17 (65%)

3 (38%)

Serious AEs

22 (27%)

3 (12%)

35 (26%)

6 (23%)

1 (13%)

AE (withdrawal)b

25 (32%)

2 (8%)

44 (32%)

7 (27%)

0

Severe AE

35 (44%)

5 (20%)

49 (36%)

4 (15%)

1 (13%)

Dose reductionc

8 (10%)

0 (0%)

11 (8%)

4 (15%)

0

  1. AE, adverse event. aExcluding current Alzheimer study. bAE leading to patient withdrawal from study. cAE leading to dose reduction.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193